Welcome to the CCO Site

Thank you for your interest in CCO content. As a guest, please complete the following information fields. These data help ensure our continued delivery of impactful education. 

Become a member (or login)? Member benefits include accreditation certificates, downloadable slides, and decision support tools.

Submit

Advances in IBD Precision Medicine With Therapeutic Drug Monitoring
  • CME
  • CE

Credits Available
Physicians: maximum of 1.0 AMA PRA Category 1 Credit
Registered Nurses: 1.0 Nursing contact hour
Released: February 16, 2022 Expiration: February 15, 2023
Start Activity
Provided by the American Gastroenterological Association, in collaboration with Clinical Care Options.

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

 

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Supported by educational grants from
Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC
Takeda Pharmaceuticals U.S.A., Inc.
Marla Dubinsky, MD
Bruce E. Sands, MD, MS

Learning Objectives

Upon completion of this activity, participants should be able to:
  • Describe the likelihood of nonresponse/loss of response with biologic therapy and the mechanisms by which these treatment failures occur
  • Define TDM regarding biologics and describe appropriate treatment changes based on TDM results
  • Review current guideline recommendations for TDM of TNF inhibitors and the latest evidence for TDM in non-TNF inhibitor biologics

Information on this Educational Activity

Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial conflicts of interest (COI) they may have with ineligible companies. All relevant COI are thoroughly vetted and mitigated according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

In accordance with the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education, all faculty and planning partners must disclose all their financial relationships with ineligible companies held within the past 24 months. The AGA Institute implements a mechanism to identify and mitigate all conflicts of interest prior to delivering the educational activity to learners.

The faculty reported the following relevant financial relationships or relationships to products or devices they have with ineligible companies related to the content of this educational activity:

Faculty

Marla Dubinsky, MD

Chief of Pediatric Gastroenterology and Nutrition
Co-Director, 
Susan and Leonard Feinstein IBD Clinical Center
Icahn School of Medicine
Mount Sinai, New York

Marla C. Dubinsky, MD, has disclosed that she has received consulting fees from AbbVie, Arena, Boehringer Ingelheim, Bristol-Myers Squibb, Celgene, F. Hoffmann-La Roche, Genentech, Gilead Sciences, Janssen, Lilly, Pfizer, Prometheus, Takeda, and UCB; funds for research support from AbbVie, Janssen, Pfizer, and Prometheus; has ownership interest and intellectual property rights in Trellus Health; and has received other financial or material support from Takeda.
Bruce E. Sands, MD, MS

Dr. Burrill B. Crohn Professor of Medicine
Chief of the Dr. Henry D. Janowitz Division of Gastroenterology

Mount Sinai Hospital
Chief, Division of Gastroenterology
Mount Sinai Health System
Director, Digestive Disease Institute
Icahn School of Medicine at Mount Sinai
New York, New York

Bruce E. Sands, MD, MS, AGAF, has disclosed that he has received consulting fees from 4D Pharma, Abivax, AbbVie, Alimentiv, Allergan, Amgen, Arena, AstraZeneca, Bacainn, Boehringer-Ingelheim, Boston Pharmaceuticals, Bristol-Myers Squibb, Calibr, Capella, Celgene, Celltrion, ClostraBio, Enthera, F.Hoffmann-La Roche, Ferring, Galapagos, Gilead, Glaxo SmithKline, GossamerBio, Immunic, Index, Innovation, Ironwood, Janssen, Kaleido, Kallyope, Lilly, MiroBio, Morphic, Oppilan, OSE, Otsuka, Palatin, Pfizer, Progenity, Prometheus, Protagonist, Q32 Bio, Redhill, Rheos, Salix, Seres, Shire, Sienna, Sun Pharma, Surrozen, Takeda, Target PharmaSolutions, Teva, Thelium, Theravance, TLL Pharma, USWM Enterprises, Ventyx, Viela Bio, Vivante, and Vivelix; funds for research support from Takeda, Pfizer, Theravance, and Janssen; and has ownership interest in Ventyx and Vivante.

Staff

Craig Borders
Vice President, Managing Scientific Director
Craig Borders has no relevant conflicts of interest to report.
Kiran D. Mir-Hudgeons, PhD

Manager, Editorial Operations

Kiran Mir-Hudgeons, PhD, has no relevant conflicts of interest to report.
Ruth Cohen Cooper, CHCP

Vice President, Science and Strategy

Ruth Cohen Cooper, CHCP, has no relevant conflicts of interest to report.
Laurie Powers, RN
Laurie Powers, RN has no relevant conflicts of interest to report

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The American Gastroenterological Association, Clinical Care Options, and the activity supporter do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the American Gastroenterological Association, Clinical Care Options, and the activity supporter. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Target Audience

This program is intended for gastroenterologists, nurse practitioners, nurses, and other healthcare providers who treat patients with IBD.

Goal

The goal of this education project is to increase the learners’ knowledge and competence in utilizing TDM to maximize the effectiveness of IBD therapies and help ensure long-term remission.

Accreditation Statement

The AGA Institute is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Credit Designation

The AGA Institute designates this enduring activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Joint Accreditation Statement

In support of improving patient care, this activity has been planned and implemented by Clinical Care Options, LLC (CCO) and the American Gastroenterological Association. Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

Nursing Continuing Education

Credit Designation

The maximum number of hours awarded for this Continuing Nursing Education activity is 1.0 contact hour.

Program Medium

This program has been made available online.

Instructions for Credit

Participation in this self-study activity should be completed in approximately 1.0 hours. To successfully complete this activity and receive credit, participants must follow these steps during the period from February 16, 2022, through February 15, 2023:

1. Register online at http://www.clinicaloptions.com.
2. Read the target audience, learning objectives, and faculty disclosures.
3. Study the educational activity online or printed out.
4. Submit answers to the posttest questions and evaluation questions online.

You must receive a test score of at least 65% and respond to all evaluation questions to receive a certificate. After submitting the evaluation, you may access your online certificate by selecting the certificate link on the posttest confirmation page. Records of all CME/CE activities completed can be found on the "CME/CE Manager" page. There are no costs/fees for this activity.

Reactive and Proactive TDM With Non-TNFs
  • CME
  • CE

Loading...
In this engaging, interactive, on-demand webcast, expert faculty review the rationale and current best practices for therapeutic drug monitoring (TDM) in patients with IBD. The data-driven discussion includes proactive and reactive TDM approaches for both TNF inhibitors and non-TNF inhibitor biologics.
Marla Dubinsky, MD
Bruce E. Sands, MD, MS
Physicians: maximum of 1.0 AMA PRA Category 1 Credit
Registered Nurses: 1.0 Nursing contact hour
Released: February 16, 2022 Expiration: February 15, 2023

This program is divided into several short segments that you can step through using the Video Chapters menu.

Related Content

Experts review new treatment strategies in IBD and how to address health inequities in patients, from Clinical Care Options (CCO)

Anita Afzali, MD, MPH, MHCM, FACG, AGAF
Program Director
David Hudesman, MD, FACG, AGAF Millie D. Long, MD, MPH, FACG, AGAF
Physicians: maximum of 1.5 AMA PRA Category 1 Credits Registered Nurses: 1.5 Nursing contact hours Physician Assistants: maximum of 1.5 hours of AAPA Category 1 CME credits Released: June 24, 2022 Expired: June 23, 2023

Drs. Anita Afzali, Millie Long, David Hudesman on latest IBD treatments, therapeutic challenges, individualized care, health inequity from Clinical Care Options (CCO)

Anita Afzali, MD, MPH, MHCM, FACG, AGAF
Program Director
David Hudesman, MD, FACG, AGAF Millie D. Long, MD, MPH, FACG, AGAF
Released: May 20, 2022

On-demand webcast featuring an expert panel with insight on new data presented at ECCO 2022 for Crohn disease and ulcerative colitis from Clinical Care Options (CCO)

Uma Mahadevan, MD Bruce E. Sands, MD, MS Physicians: maximum of 0.75 AMA PRA Category 1 Credits Released: May 19, 2022 Expired: May 18, 2023

Clinical Care Options (CCO) presents expert commentary on new data in Crohn disease and ulcerative colitis from ECCO 2022

Bruce E. Sands, MD, MS Released: May 13, 2022

Video Chapters


Provided by the American Gastroenterological Association, in collaboration with Clinical Care Options.

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

 

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Supported by educational grants from
Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC
Takeda Pharmaceuticals U.S.A., Inc.

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue

Cookie Settings